This trial is intended to understand how the body processes repinatrabit in people with moderate liver impairment and severe kidney impairment and also to compare these results with people of similar age, weight, and sex who have normal liver function.
Body mass index (BMI) from 18.0 to 38.0 kilograms per square meter (kg/m²) (inclusive).
Able to provide written, informed consent.
Male participants and female participants of childbearing potential (POCBP) must agree to remain fully abstinent from intercourse where pregnancy can occur OR practice 2 different contraceptive methods, where at least one must be highly effective.
Otherwise be in generally good health.
Participants who are breastfeeding.
Participants who have a positive pregnancy test result prior to receiving the investigational medical product (IMP).
Participants with international normalized ratio (INR) greater than (>) 2.3. Participants with hepatic impairment with elevated INR will be excluded based on the investigator's discretion.
Participants with hepatic carcinoma or porto-hepatic shunts that have been surgically created or planted.